SenesTech Inc (NASDAQ:SNES) has earned a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy rating.

Brokerages have set a 1-year consensus price objective of $9.38 for the company and are predicting that the company will post ($0.19) earnings per share for the current quarter, according to Zacks. Zacks has also assigned SenesTech an industry rank of 108 out of 265 based on the ratings given to its competitors.

Several research firms have issued reports on SNES. Zacks Investment Research lowered shares of SenesTech from a “hold” rating to a “sell” rating in a research report on Friday, September 15th. Craig Hallum set a $3.00 price target on shares of SenesTech and gave the stock a “buy” rating in a research report on Wednesday, November 22nd. Finally, Roth Capital decreased their price target on shares of SenesTech from $3.75 to $14.00 and set a “buy” rating on the stock in a research report on Thursday, December 28th.

A number of institutional investors have recently bought and sold shares of the business. Gilder Gagnon Howe & Co. LLC grew its position in SenesTech by 3.0% in the third quarter. Gilder Gagnon Howe & Co. LLC now owns 1,078,499 shares of the company’s stock worth $1,995,000 after buying an additional 31,330 shares during the last quarter. Prudential PLC grew its position in SenesTech by 49.3% in the second quarter. Prudential PLC now owns 447,971 shares of the company’s stock worth $2,661,000 after buying an additional 147,971 shares during the last quarter. TCI Wealth Advisors Inc. acquired a new position in SenesTech in the third quarter worth approximately $748,000. Skylands Capital LLC grew its position in SenesTech by 139.8% in the third quarter. Skylands Capital LLC now owns 87,483 shares of the company’s stock worth $162,000 after buying an additional 51,000 shares during the last quarter. Finally, White Pine Capital LLC acquired a new position in SenesTech in the 2nd quarter worth approximately $110,000. Hedge funds and other institutional investors own 14.44% of the company’s stock.

SenesTech (NASDAQ SNES) remained flat at $$0.71 during trading on Wednesday. The company had a trading volume of 5,561 shares, compared to its average volume of 230,617. The company has a quick ratio of 2.67, a current ratio of 2.94 and a debt-to-equity ratio of 0.17. The stock has a market cap of $11.17 and a price-to-earnings ratio of -0.53. SenesTech has a 1-year low of $0.56 and a 1-year high of $10.69.

SenesTech (NASDAQ:SNES) last posted its quarterly earnings results on Wednesday, November 8th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.31) by $0.03. The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.25 million. SenesTech had a negative net margin of 14,473.40% and a negative return on equity of 190.41%. analysts expect that SenesTech will post -1.16 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “SenesTech Inc (SNES) Given $9.38 Average Price Target by Brokerages” was first posted by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.dailypolitical.com/2018/01/10/senestech-inc-snes-given-9-38-average-price-target-by-brokerages.html.

SenesTech Company Profile

SenesTech, Inc is a United States-based biotechnology platform and research company. The Company is engaged in developing a technology for managing animal populations by fertility control. It offers ContraPest, a fertility control product candidate. ContraPest’s technology and approach targets the reproductive capabilities of both sexes.

Get a free copy of the Zacks research report on SenesTech (SNES)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for SenesTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SenesTech and related companies with MarketBeat.com's FREE daily email newsletter.